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Abstract
Background: Venous thrombosis is a common disease with a high mortality rate shortly after the event. However, details on
long-term mortality in these patients are lacking. The aim of this study was to determine long-term mortality in a large
cohort of patients with venous thrombosis.
Methods and Findings: 4,947 patients from the Multiple Environmental and Genetic Assessment study of risk factors for
venous thrombosis (MEGA study) with a first nonfatal venous thrombosis or pulmonary embolism and 6,154 control
individuals without venous thrombosis, aged 18 to 70 years, were followed up for 8 years. Death and causes of death were
retrieved from the Dutch death registration. Standardized mortality ratios (SMRs) were calculated for patients compared
with control individuals. Several subgroups were studied as well. 736 participants (601 patients and 135 controls) died
over a follow-up of 54,948 person-years. The overall mortality rate was 22.7 per 1,000 person-years (95% CI 21.0–24.6) for
patients and 4.7 per 1,000 person-years (95% CI 4.0–5.6) for controls. Patients with venous thrombosis had a 4.0-fold (95% CI
3.7–4.3) increased risk of death compared with controls. The risk remained increased up to 8 years after the thrombotic
event, even when no additional comorbidities were present. The highest risk of death was found for patients with additional
malignancies (SMR 5.5, 95% CI 5.0–6.1). Main causes of death were diseases of the circulatory system, venous thrombosis,
and malignancies. Main limitation was a maximum age of 70 at time of inclusion for the first event. Therefore results can not
be generalized to those in the highest age categories.
Conclusions: Patients who experienced a first venous thrombosis had an increased risk of death which lasted up to 8 years
after the event, even when no comorbidities were present at time of thrombosis. Future long-term clinical follow-up could
be beneficial in these patients.
Please see later in the article for the Editors’ Summary.
Citation: Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR (2012) Long-Term Survival in a Large Cohort of Patients with Venous Thrombosis:
Incidence and Predictors. PLoS Med 9(1): e1001155. doi:10.1371/journal.pmed.1001155
Academic Editor: Mervyn Singer, University College London, United Kingdom
Received May 27, 2011; Accepted November 29, 2011; Published January 10, 2012
Copyright:  2012 Flinterman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis was supported by grant NHS 98.113 from the Netherlands
Heart Foundation, grant RUL 99/1992 from the Dutch Cancer Foundation, and grant 912-03-033|2003 from the Netherlands Organisation for Scientific Research.
The follow-up of this study was supported by grant 2008B086 from the Netherlands Heart Foundation. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: DVT, deep vein thrombosis; HR, hazard ratio; MEGA, Multiple Environmental and Genetic Assessment; PE, pulmonary embolism; SMR,
standardized mortality ratio
* E-mail: f.r.rosendaal@lumc.nl
PLoS Medicine | www.plosmedicine.org 1 January 2012 | Volume 9 | Issue 1 | e1001155Introduction
Venous thrombosis is a multicausal disease that occurs in one to
three per 1,000 persons per year [1–3]. Venous thrombosis is
associated with considerable morbidity and mortality. About 10%–
20% of patients develop a recurrence within 5 y [4–6], and up to
50%develop post-thrombotic syndromewithinseveralmonthsafter
the thrombotic event [7]. The mortality rate after venous
thrombosis is about 20% within 1 y [2,8]. Mortality is 2- to 4-fold
higher for patients with pulmonary embolism (PE), of whom 10%–
20% die within 3 mo after the event, than for patients with a deep
vein thrombosis (DVT) of the leg [2,9–11]. Malignancy is the main
causeofdeath;however,when onlypatientswithout malignancyare
followed, 12% die within a year after the thrombosis [2,12].
Another predictor is the underlying cause of the first thrombosis,
wherethoseindividualswiththromboticeventsprovoked bysurgery
or trauma have a lower 3-y mortality risk than those with idiopathic
thrombosis [2]. These figures imply that venous thrombosis has a
major impact on survival. It is currently unknown whether this poor
prognosis is limited to the period shortly after the thrombotic event,
or persists for extended periods.
In the present study we determined long-term survival in a large
cohort of consecutive patients with a first venous thrombosis
compared with age- and sex-matched individuals without venous
thrombosis, who were all followed for up to 8 y.
Methods
Ethics Statement
This study was approved by the Ethics Committee of the Leiden
University Medical Center and written informed consent was
obtained from all the participants. The investigation has been
conducted according to the principles expressed in the Declaration
of Helsinki.
Study Population and Data Collection
We used a cohort consisting of all patients and control
individuals from the Multiple Environmental and Genetic
Assessment of risk factors for venous thrombosis study (MEGA
study). Details of the study are described elsewhere [12,13]. In
short, the MEGA study was set up as a case-control study
including 4,965 consecutive patients aged 18 to 70 y with a first
objectively verified venous thrombosis of the leg or PE and 6,297
control individuals recruited between March 1999 and September
2004.
Patients were recruited from six anticoagulation clinics in the
Netherlands, which exclusively monitor out-patient treatment with
vitamin K antagonists in well-defined geographical regions.
Patients were included in the study after a median period of
1 mo (range 13–64 d) after the diagnosis of thrombosis.
The control group consisted of partners of patients (n=3,297)
and a random control group matched on age and sex (n=3,000),
recruited between January 2002 and December 2004 using
random digit dialing. All patients and controls filled in a detailed
questionnaire on risk factors for venous thrombosis and several
comorbidities present at time of venous thrombosis (patients) or at
time of inclusion in the study (controls).
Vital status was ascertained through community registries,
where all inhabitants are registered. Causes of death were obtained
from the Central Bureau of Statistics Netherlands, the national
repository for death certificates. Both primary and secondary
causes of deaths were retrieved. Causes of death were coded
according to the ICD-10 classification [14,15].
In the current study an additional control group was used. We
compared cause-specific death rates of the patients to those of the
general Dutch population, which, because of the size of the
reference group, allowed analyses of cause-specific death rates, for
which the control group of the MEGA study was too small.
Follow-Up and Statistical Analysis
The observation time was from 30 d after the venous
thrombosis, or a similar date in the thrombosis-free cohort, to
either death, end of follow-up (between February 2007 and May
2009), emigration (n=164, 1.5%), or loss to follow-up (n=173,
1.5%), whichever occurred first.
For 152 individuals (1.4%, nine patients) follow-up was less than
30 d, and they were excluded. Censoring due to emigration
concerned 164 individuals (1.5%) and to loss to follow-up 173
individuals (1.5%). This figure implies that follow-up was complete
for 97% of the cohort. Vital status was obtained from the
community registries and date of retrieving vital status was used as
end date of follow-up, if patients were still alive. It was not possible
to retrieve all vital statuses at the same date. Therefore, the end
date of follow-up lies between February 2007 and May 2009.
The cohort of thrombosis-free individuals has a mortality that
was exactly equal to the general population (standardized
mortality ratio [SMR] 1.0, 95% CI 0.9–1.2), and there were no
differences in mortality within the thrombosis-free cohort, between
those who were recruited as partners of thrombosis patients or by
random digit dialing.
Cumulative incidences and mortality rates were calculated at 1,
5, and 8 y of follow-up. Survival was estimated and visualized by
Kaplan-Meier life-tables and survival curves.
SMRs were calculated to estimate relative rates of all cause
mortality, e.g., by type of initialthrombosis. The SMR is the ratio of
the observed number of deaths over the number of deaths expected
when the mortality rate in the cohortof patients, withits specific age
and sex distribution, was the same as that in the reference group.
SMRs were calculated for the complete cohort of patients and for
severalsubgroupsofvenousthrombosispatients:(1)forpatientswith
active malignancy at time of inclusion or diagnosed within 6 mo
after thrombosis; (2) for patients with a provoked first thrombosis
without malignancy; (3) for patients with an idiopathic first
thrombosis; and (4) according to type of first venous thrombosis
(PE or DVT). An idiopathic thrombosis was defined as a thrombosis
not related to surgery, hospital admission, injury, plaster cast, active
malignancy, oral contraceptive use, or pregnancy, all in the year
previous to the thrombotic event or during puerperium. SMRs for
these categories of patients were calculated with the mortality rates
of the complete control group as a reference; and also using only the
rates of the controls belonging to the same category (e.g., patients
with a provoked event were compared to controls who also had had
surgery or plaster cast, etc.). This latter analysis was performed to
estimate the effect of venous thrombosis on survival conditional on
other risk factors for thrombosis.
Hazard ratios (HRs) of death from all causes per year of follow-
up were calculated to estimate the decrease of mortality over time
for the different subgroups. To calculate the HRs per year the
hazard of dying in year X was calculated with all persons that
survived up to year X. If they survived the whole of year X they
were censored at the end of that year.
To calculate the reduction in median life expectancy we used
the average life table of the birth cohorts of 1935–1965 of the
Dutch population to create a population comparable in life
expectancy to the MEGA study. To estimate the median life
expectancy for the nonmalignant patients we multiplied the death
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thrombosis by sex. The median life expectancy is the age at which
half of a birth cohort of newborns had died. For this calculation we
assumed an equal distribution of relative mortality after throm-
bosis in our population.
The influence of the presence of concurrent disease at the time
of thrombosis on mortality was assessed by contrasting the patient
cohort with the thrombosis-free cohort by Cox regression in strata
of participants with or without concurrent diseases present. In
addition, the annual HRs were adjusted for the number of
Table 1. Baseline characteristics of the study population.
Characteristics Percent Patients, n=4,947 (n) Percent Controls, n=6,154 (n)
Sex (% men) 46 (2,271) 46 (2,854)
Mean age at index (range)
a 49 (18–70) 47 (18–70)
Median age at index (range)
a 50 (18–70) 48 (18–70)
Malignancy
b 13 (619) 4 (233)
Diabetes 3.7 (183) 3.2 (195)
Liver disease 0.5 (27) 0.3 (20)
Kidney disease 1.2 (59) 0.4 (23)
Myocardial infarction 2.8 (137) 1.8 (113)
Heart failure 1.2 (76) 1.0 (60)
Stroke or hemorrhage of the brain 3.0 (154) 1.8 (115)
Chronic bronchitis 5.1 (253) 2.7 (165)
Emphysema 1.3 (66) 0.6 (35)
Multiple sclerosis 0.5 (30) 0.3 (17)
Rheumatoid arthritis 3.0 (144) 2.1 (132)
aIndex date was date of thrombosis for patients and date of participation in the study for control individuals.
bMalignancy at time of or within 6 mo after the index date types of cancer have been previously reported [12].
doi:10.1371/journal.pmed.1001155.t001
Figure 1. Kaplan-Meier survival curves for patients and controls.
doi:10.1371/journal.pmed.1001155.g001
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model. Concurrent diseases were diabetes, liver disease, kidney
disease, heart failure, rheumatoid arthritis, chronic bronchitis,
emphysema, myocardial infarction, stroke or hemorrhage of the
brain, surgery 3 mo prior to thrombosis, and multiple sclerosis.
HRs were adjusted for sex and age. The assumption of
proportionality was tested both visually from the Kaplan-Meier
curve, and statistically, with the proportional hazard test provided
by the software package used.
For the analysis of cause-specific mortality SMRs were
calculated with the rates from the general population as reference.
Analyses were performed using STATA 10.1. (Stata Corporation).
Results
Baseline Characteristics
4,947 patients with a first venous thrombosis and 6,154 controls
were followed during a total period of 26,515 and 28,433 person-
years, respectively. The baseline characteristics of patients and
controls are described in Table 1. Median duration of follow-up
was 5.5 y (range 1 mo–9.9 y) for patients and 4.4 y (range 1 mo–
9.1 y) for controls. 601 patients (12%) and 135 controls (2%) died.
Median time between inclusion and death was 1.7 y (range 36 d–
9.2 y) for patients and 2.9 y (range 57 d–8.1 y) for controls.
Overall Mortality
The overall mortality rate after thrombosis was 22.7 per 1,000
person-years (95% CI21.0–24.6), and the overallmortality rate for the
control individuals was 4.7 per 1,000 person-years (95% CI 4.0–5.6).
Figure 1 shows an increased risk of mortality for all patients compared
with controls and for patients without malignancy compared with
control individuals up to 8 y after the thrombotic event.
Mortality of Patients with Malignancy
Patients with venous thrombosis and malignancy had, as
expected, the highest risk of mortality. Overall, 55% of the patients’
with malignancy and thrombosis died during follow-up, half of
whom during the first year after thrombosis (Table 2). Patients with
malignancy had a 17-fold increased risk of death (SMR 17.2; 95%
CI 15.5–19.1) compared to the control group. Remarkably, when
patients with malignancy and thrombosis were compared with
individuals with malignancy without thrombosis they still had a five
times higher rate of death (SMR 5.5; 95% CI 5.0–6.1) (Table 3).
Table 2. Cumulative incidences of mortality for different subgroups and controls overall, during the first year and during the first
5 y of follow-up.
Groups n at Risk 1 y 5 y Overall (8 y)
n Deaths
Percent Cumulative
Incidence (95% CI) n Deaths
Percent Cumulative
Incidence (95% CI) n Deaths
Percent Cumulative
Incidence (95% CI)
Patients 4,947 197 4.0 (3.4–4.5) 500 10.1 (9.3–10.9) 601 12.1 (11.6–13.4)
Malignancy+ 650 165 25.4 (22.0–28.7) 332 51.1 (47.2–54.9) 358 55.1 (51.3–58.9)
Malignancy2 4,297 32 0.7 (0.5–1.0) 168 3.9 (3.3–4.5) 243 5.7 (5.0–6.3)
Provoked
a 2,949 21 0.7 (0.4–1.0) 94 3.2 (2.6–3.8) 122 4.1 (3.4–4.9)
Idiopathic
b 1,348 11 0.8 (0.3–1.3) 74 5.5 (4.3–6.7) 121 9.0 (7.5–10.5)
Controls 6,154 19 0.3 (0.2–0.4) 112 1.8 (1.5–2.2) 135 2.2 (1.8–2.6)
aIndividuals with malignancy excluded.
bIdiopathic venous thrombosis were those without malignancy, surgery, hospital admission, injuries, plaster, oral contraceptive use, and pregnancy or puerperium.
doi:10.1371/journal.pmed.1001155.t002
Table 3. Standardized mortality ratios.
Groups n Patients (Events) SMR Overall (95% CI)
a SMR Specific (95% CI)
b
Overall 4,947 (601) 4.0 (3.7–4.3) 4.0 (3.7–4.3)
Malignancy+ 650 (358) 17.2 (15.5–19.1) 5.5 (5.0–6.1)
Malignancy2 4,297 (243) 1.9 (1.7–2.1) 2.2 (1.9–2.5)
DVT 2,505 (144) 1.9 (1.7–2.3) 2.3 (1.9–2.7)
PE 1,257 (72) 1.9 (1.5–2.4) 2.2 (1.7–2.8)
DVT+PE 535 (27) 1.6 (1.1–2.3) 1.8 (1.2–2.6)
Provoked
c 2,949 (122) 1.9 (1.6–2.2) 2.1 (1.8–2.5)
Idiopathic
d 1,348 (121) 1.9 (1.6–2.3) 2.2 (1.8–2.6)
aSMRs are calculated with the nonthrombosis cohort as a reference.
bSMRs are calculated with the controls with the same selection criteria as the patients as a reference.
cIndividuals with malignancy excluded.
dIdiopathic venous thrombosis were those without malignancy, surgery, hospital admission, injuries, plaster, oral contraceptive use, and pregnancy or puerperium.
DVT, patients with a first venous thrombosis of the leg without malignancies; DVT+PE, patients diagnosed with both PE and DVT without malignancies; PE, patients with
a first PE without a diagnosis of a DVT without malignancies.
doi:10.1371/journal.pmed.1001155.t003
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Patients with venous thrombosis without malignancy had an
overall 2-fold increased risk of mortality compared to the control
group (Table 3). The risk was comparable for patients with
different forms of thrombosis (DVT versus PE) and for patients
with a provoked or an idiopathic thrombosis.
Table 4 shows the HRs year by year during follow-up. The
relative risk of death was highest during the first 3 y, in all groups.
Overall, patients with thrombosis had a persistent elevation in the
risk of death, except for those with transient provoking factors; in
this group the risk became, over time, similar to that of individuals
who had provoking factors at baseline but did not suffer
thrombosis. In contrast, for those who suffered idiopathic
thrombosis, the risk of death remained over 2-fold increased up
to 8 y after the thrombosis.
The reduction of median life expectancy for those without
malignancy was 5 y for men and women. The estimated median
life expectancy was 76 for men and 79 for women compared to 81
and 84 y respectively for the Dutch population.
Comorbidity
Patients with thrombosis and without malignancy have an
increased risk of death, which could be explained by concurrent
other major disorders (Table 4). When we stratified our study
population for those with and without concurrent disorders we
found no difference in risk of death in the stratum of
participants with comorbidities (HR 1.2 [0.9–1.7] for patients
with venous thrombosis compared to controls). However, for
patients without concurrent major disorders at time of
thrombosis overall a HR of 2.5 (95 CI% 1.9–3.4) was found
compared to controls without concurrent disorders and
thrombosis. The increased risk of death among patients with
venous thrombosis can therefore not be fully explained by the
presence of these concurrent disorders.
Causes of Death
The main primary cause of death was malignancy (n=392,
65%) followed by diseases of the circulatory (n=80, 13%) and
respiratory (n=34, 6%) systems (Table 5). 24 patients died of PE
(which is classified under circulatory) either as primary cause
(n=7) or as a complication (n=17).
Cause-specific mortality was compared with data from the
general population. Patients had two times higher rates of deaths
from diseases of the circulatory system (n=80, SMR 2.0, 95% CI
1.6–2.5) and three times higher death rates of diseases from the
respiratory system (n=34, SMR 3.3, 95% CI 2.3–4.6) than the
general population. Venous thrombosis and malignancy were the
causes of death with the highest SMR compared to the general
population (Table 5). Patients who died of diseases of the
respiratory system mainly died of chronic obstructive pulmonary
diseases or pneumonia as primary cause of death. Five patients
died of either a subarachnoid or intracerebral hemorrhage of
whom three were on anticoagulation treatment at time of death.
For patients without malignancy the main causes of death were
diseases of the respiratory system and diseases of the circulatory
system (SMR 3.3, 95% CI 2.3–4.8 and 2.2, 95% CI 1.7–2.7,
respectively). Compared with the general population they did not
have an increased risk of death due to malignancies (Table 5).
Discussion
We studied long-term mortality after a first venous thrombosis
in 4,947 patients followed for a median period of 5.5 y, compared
with a thrombosis-free cohort of 6,154 individuals. The overall
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Overall, the death rate in patients was 4.0-fold increased and in
those without a malignancy over two-fold increased. In all patients
except those with a transient provoking risk factor underlying the
initial event, death rates remained elevated up to 8 y after the
thrombotic event.
Few studies have studied the long-term risk of mortality after
venous thrombosis. In a previous study from Norway, the
cumulative incidences at 1 y were much higher than those we
found. In the Norwegian study a cumulative incidence at 1 y of
14.5% was found for cases with an idiopathic venous thrombosis,
of 9.7% for provoked cases, and of 63.4% for cancer patients,
while we found cumulative incidences of 0.8%, 0.7%, and 25.4%,
respectively [2]. These differences result from the inclusion of
inpatients in the Norwegian study, thereby also counting early
deaths, and the inclusion of patients of all ages, while our study
was restricted to patients younger than 70 y at the time of the first
event. This study design implies that overall mortality in patients
with venous thrombosis is even higher than we report. Because of
our extended follow-up for up to 8 y after the thrombotic event,
our most important observation is that increased mortality for
thrombosis patients persists for a prolonged time. Furthermore, we
showed that, when only the long-term survival is taken into
account, there is no longer a difference in survival for patients with
a DVT and PE. This finding indicates that the highly increased
risk of death for those with PE is mainly present during the first
month after venous thrombosis. Recently, an Austrian study did
not find an increased risk of long-term mortality for patients with
venous thrombosis [16]. However, they included patients at a
median time of 14 mo after thrombosis up to 6 y after the
thrombotic event. Because of this delayed inclusion only long-term
survivors of thrombosis were included in the Austrian study and
therefore no increase in mortality was found.
We confirmed previous observations that patients with malig-
nancy and venous thrombosis have a very poor prognosis,
substantially worse than patients with cancer without thrombosis,
with a 5.5-fold difference in our study [17,18]. Although death
from recurrent thrombosis was clearly elevated after a first
thrombotic event, most patients died of other causes, mainly of
the circulatory system. While one is tempted to explain this by
preexisting comorbid conditions, death rates were also persistently
elevated after idiopathic thrombosis and in those without any
major illnesses.
Main causes of death, apart from malignancies, were diseases of
the circulatory and respiratory system. These results are in line
with previous studies that described associations between risk
factors for venous and arterial thrombosis as well as an increased
risk of arterial thrombosis for those who experienced venous
thrombosis [19–21]. Alternatively, misclassification of cause of
death may explain (part of) the results, especially when no further
research into the cause of death was performed, although one
would expect this to affect the results in the opposite direction
(patients with previous PE may be more readily misclassified as
having died of PE than of other lung diseases than those without a
history of PE).
Our study may have suffered from some limitations: as discussed
above causes of death were not objectively verified. However
misclassification by the physician determining the cause of death is
most likely to have been equal in this population and in the general
population, which would have led to an underestimation of the
risks we have found. Furthermore, we only recruited patients after
discharge from hospital, and therefore overall mortality is
underestimated. Moreover, our results cannot be extrapolated to
patients older than 70 y at the time of thrombosis, or to children.
Among the major strengths of this study are the large size of the
cohort, and the long follow-up period. Mortality data were
retrieved from the national registry where 98.5% of participants
were found. Therefore, loss to follow-up was minimal and dates of
death were accurate. To our knowledge, this has been the first
study to calculate mortality rates compared with the general
population and compared to specific control groups. Therefore,
we were able to define overall risks of death up to 8 y after
thrombosis as well as the risk for several subgroups. Our results
underline the major consequences of venous thrombosis, not only
with regard to morbidity but also to mortality.
Acknowledgments
We acknowledge the directors of the Anticoagulation Clinics of Amersfoort
(M.H.H. Kramer), Amsterdam (M. Remkes), Leiden (F.J.M. van der
Meer), The Hague (E. van Meegen), Rotterdam (A.A.H. Kasbergen), and
Utrecht (J. de Vries-Goldschmeding) who made the recruitment of patients
possible; and the interviewers J.C.M. van den Berg, B. Berbee, S. van der
Leden, M. Roosen, and E.C. Willems of Brilman. We thank I. de Jonge, R.
Roelofsen, M. Streevelaar, L.M.J. Timmers, and J.J. Schreijer for their
secretarial, administrative support, and data management, and I. de Jonge
and I.A. Noordermeer for collecting vital status from the community
Table 5. Increased mortality per cause of death compared with the Dutch population.
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I61 Cerebral Hemorrhage 4 (0.6) 1.9 (0.7–5.0) 2 (1) 1.1 (0.3–4.5)
I63 Cerebral infarction 1 (0.1) 0.7 (0.1–5.0) 1 (0.5) 0.8 (0.1–5.9)
I64 Stroke 2 (0.3) 0.8 (0.2–3.3) 2 (1) 1.0 (0.2–4.0)
I26 and I80 Venous thromboembolism 7 (1) 5.5 (2.6–11.4) 7 (3) 6.5 (3.1–13.7)
C00–C99 Neoplasms 392 (65) 5.5 (5.0–6.0) 69 (29) 1.1 (0.9–1.4)
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J44 Chronic obstructive pulmonary disease 19 (3) 3.7 (2.4–5.8) 16 (7) 3.7 (2.3–6.1)
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Background The term venous thrombosis describes the
clinical situation—more common during pregnancy, after
surgery, or serious illness—in which a blood clot lodges in a
vein. One specific type, which is more serious, involves the
clot forming in a major vein in the lower leg and thigh and is
termed a deep venous thrombosis. The clot can block blood
flow and cause swelling and pain, but more seriously, can
break off and move through the bloodstream, causing an
embolism. An embolism can get stuck in the brain (and
cause a stroke), lungs (and cause a pulmonary embolism),
heart (to cause a heart attack), and/or other areas of the
body, leading to severe damage.
Venous thrombosis is known to be associated with
considerable short-term morbidity and mortality: the mor-
tality rate after venous thrombosis is about 20% within one
year and studies to date have suggested that the mortality
rate is two to four times higher for patients with pulmonary
embolism, of whom 10%–20% die within three months after
the event. Many factors are associated with venous
thrombosis, and the underlying cause of the thrombosis
affects survival; for example, those with thrombotic events
provoked by surgery or trauma have a lower mortality risk
than patients with thrombosis caused by malignancy.
Furthermore, about 10%–20% of patients who have had a
venous thrombosis develop a recurrence within five years
and up to 50% develop post-thrombotic syndrome—long-
term swelling, pain, and changes in skin color.
Why Was This Study Done? It is currently unknown
whether the poor prognosis associated with venous
thrombosis is limited to the months following the
thrombotic event, or persists for years afterwards. So in
this study, the researchers sought to answer this question by
analyzing the long-term survival in a large cohort of patients
who had experienced a first venous thrombosis and who
were all followed for up to eight years.
What Did the Researchers Do and Find? The researchers
used the Multiple Environmental and Genetic Assessment of
risk factors for venous thrombosis study (MEGA study), which
was a case-control study involving 4,965 consecutive
patients aged 18 to 70 years who were objectively
diagnosed with a deep venous thrombosis or pulmonary
embolism and recruited from six anticoagulation clinics in
the Netherlands between March 1999 and September 2004.
The control group consisted of partners of patients
(n=3,297) and a random control group matched on age
and sex (n=3,000). The researchers obtained causes of death
from the Central Bureau of Statistics and for the observation
period (30 days after the venous thrombosis, to either death
or end of follow-up between February 2007 and May 2009)
compared cause-specific death rates of the patients to those
of the general Dutch population. The researchers devised
specialist survival models (called Kaplan-Meier life-tables)
and calculated standardized mortality ratios (SMRs—the
ratio of the observed number of deaths over the number of
deaths expected) to estimate relative rates of all cause
mortality by type of the initial thrombosis and the underlying
cause.
Using these methods, the researchers found that the overall
mortality rate in patients with thrombosis was substantially
greater than in the control group (22.7 per 1,000 person-
years compared to 4.7 per 1,000 person-years). Apart from
malignancies, the researchers found that the main causes of
death were diseases of the circulatory and respiratory
system. Patients with venous thrombosis and malignancy
had the highest risk of mortality: 55% died during follow-up.
Patients with venous thrombosis without malignancy had an
overall 2-fold increased risk of mortality compared to the
control group and this risk was comparable for patients with
different forms of thrombosis (such as deep venous
thrombosis and pulmonary embolus). According to the
researchers’ calculations, the relative risk of death was
highest during the first three years after thrombosis, but
for those with thrombosis of unknown cause, the risk of
death increased by two-fold up to eight years after the
thrombosis. Furthermore, the researchers found that the
highly increased risk of death for those with pulmonary
embolism is mainly only for the first month as long-term
survival is similar to that of patients with a deep venous
thrombosis.
What Do These Findings Mean? These findings show
that patients who have experienced a venous thrombosis for
the first time have an increased risk of death, which may last
up to eight years after the event. These findings have
important clinical implications and suggest that long-term
clinical follow-up could be beneficial in patients who have
experienced a venous thrombosis for the first time.
Additional Information Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001155.
N Wikipedia provides information about venous thrombosis
note that Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
N Medline has patient-friendly information about deep
venous thrombosis and pulmonary embolism
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